Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate-Reference-Cited by-同舟云学术

Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate

Published:2017-10-03 Issue:1 Volume:34 Page:107-115
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Williams Mitzi J.¹,Johnson Kristen²,Trenz Helen M.³,Korrer Stephanie³,Halpern Rachel³,Park Yujin⁴,Herrera Vivian²

Affiliation:

1. Multiple Sclerosis Center of Atlanta, Atlanta, GA, USA;

2. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA;

3. Optum, Eden Prairie, MN, USA;

4. University of Maryland School of Pharmacy, Baltimore, MD, USA

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2017.1374937

Reference41 articles.

1. Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies

2. National Multiple Sclerosis Society. What is MS? 2016. Available at: http://www.nationalmssociety.org/What-is-MS. [Last accessed 8 March 2016]

3. Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis

4. Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of oral disease-modifying agents and their adherence trajectories with annual relapses in multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-05

2. Treatment Patterns by Race and Ethnicity in Newly Diagnosed Persons with Multiple Sclerosis;Drugs - Real World Outcomes;2023-09-21

3. Comparative adherence trajectories of oral disease‐modifying agents in multiple sclerosis;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-05-22

4. Health Disparities, Inequities, and Social Determinants of Health in Multiple Sclerosis and Related Disorders in the US;JAMA Neurology;2021-12-01

5. Racial and ethnic disparities in treatment response and tolerability in multiple sclerosis: A comparative study;Multiple Sclerosis and Related Disorders;2021-11